230 filings
Page 5 of 12
6-K
i6pd 0dfm
1 Jul 22
Current report (foreign)
4:00pm
6-K
ytnsz mlzii41tgz8
29 Jun 22
SciSparc Successfully Completed The Development of its Proprietary Drug Candidate SCI-110 for its Upcoming Phase IIb Study In Tourette Syndrome
8:36am
6-K
adw5fz6
24 Jun 22
SciSparc Announces Ethics Committee Approval to Conduct its Clinical Trial in Autism Spectrum Disorder
8:52am
6-K
ed4s4u3s
9 Jun 22
SciSparc’s Board of Directors Provides Strategic Decision
8:38am
6-K
h5z9l jnaj
2 Jun 22
Report of Foreign Private Issuer
4:30pm
6-K
5wds bw8gu
1 Jun 22
SciSparc to Collaborate with Polyrizon for Brain Targeting Using Intranasal Hydrogel Systems
4:11pm
6-K
zwuakk
27 May 22
SciSparc Announces Pricing of $10 Million Private Placement Priced At-the-Market
4:10pm
6-K
xoro b0p9
26 May 22
SciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial in Tourette Syndrome
8:33am
6-K
wpk0kfo
24 May 22
SciSparc and Clearmind Medicine Inc. Collaboration Yields Positive Results for its Psychedelic Combination Treatment
8:31am
6-K
tufvd9fwv3aoo74 kiiv
11 May 22
SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields New Patent Application for Psychedelic Combination Treatment for Binge Behaviors
1:58pm
6-K
vrr07wgw43y sm
1 Apr 22
SciSparc Announces Closing of New JV Targeting Discovery of Potential Drugs for Cancers and Infectious Diseases
6:02am
6-K
pbe0fw7i4rdrnj t68
17 Mar 22
SciSparc Announces Positive Results from Psychedelic-Based Pre-Clinical Trial
9:06am
6-K
nnljv71
15 Mar 22
Report of Foreign Private Issuer
7:37pm
6-K
9dq096yhx5q oxg0u
10 Mar 22
SciSparc Launches New JV Targeting Discovery of Potential Drugs for Cancers and Infectious Diseases
10:16am
6-K
1diwei sgulh3bvt0a
9 Mar 22
SciSparc Enters Collaboration for the Development of Innovative Psychedelic-Based Pharmaceuticals
10:59am
6-K
nfonc8g5 1q
22 Feb 22
Report of Foreign Private Issuer
9:05am
6-K
attu t62z3n
17 Feb 22
Report of Foreign Private Issuer
4:00pm
6-K
tg7h6lmkffp6spf8fv
10 Feb 22
Report of Foreign Private Issuer
4:00pm
6-K
sbtx5
18 Jan 22
SciSparc Advances Its Phase IIb Clinical Trial in Patients with Tourette Syndrome with its Proprietary Drug Candidate SCI-110
4:27pm
6-K
therjhyzcje5qlt
6 Jan 22
Report of Foreign Private Issuer
4:02pm